While potential Trump tariffs spark investor anxiety, a far more critical risk is unfolding in Asia. Are you prepared?

We take a look at 4 Pharma & Biotech companies whose share prices rallied in October on the back of positive announcements.

There may not be industry-wide reporting just yet but transparency around returns and fees are finally coming through in ...

Whilst Zoom has made communicating with companies far more efficient, at NAOS we still believe that nothing beats a ...

Australian investors have long favoured traditional assets, like stocks, bonds, and brick-and-mortar property.

Despite pressure on consumer spending, consumers prioritise trusted brands for their health-related needs and Haleon is a ...

And why Lazard Asset Management's June-Yon Kim believes investors can expect improving earnings growth from Japanese ...